| Old Articles: <Older 4691-4700 Newer> |
|---|
 |
The Motley Fool
March 28, 2008
Brian Orelli |
Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.   |
The Motley Fool
March 28, 2008
Brian Lawler |
Pfizer Gets the Signal to Steal Pfizer's acquisition of Encysive Pharmaceuticals is set for Monday. |
The Motley Fool
March 28, 2008
Brian Lawler |
Amgen and Roche Still Duking It Out Amgen threatens to sue Roche for damages. |
The Motley Fool
March 28, 2008
Brian Orelli |
The Yin and Yang of Schering's Label Changes Schering gets a pair of label changes that have opposite effects for its hepatitis C drug. |
The Motley Fool
March 28, 2008
Brian Orelli |
Allergic Reaction to Singulair News? The FDA warns the public about potential side effects of Merck's allergy treatment Singulair. |
Financial Planning
April 1, 2008
Elizabeth O'Brien |
Prognosis: Mixed Healthcare stocks do tend to outperform in a weak economy. But lackluster drug pipelines and other pressures mean that the traditional definition of this industry as a refuge may not be as true as in the past. |
The Motley Fool
March 27, 2008
Brian Orelli |
Tougher Rules Could Help Stent Makers The FDA has finally issued draft guidance on the minimum requirements that it thinks companies need to fulfill to get drug-eluting stents approved. |
The Motley Fool
March 27, 2008
Brian Orelli |
I Heart the ACC What can investors expect from this weekend's blood-pumping American College of Cardiology scientific meeting? |
The Motley Fool
March 27, 2008
Brian Lawler |
Eli Lilly Hands Over Cold Cash Lilly loses to the state of Alaska in a courtroom battle over its top drug Zyprexa. |
The Motley Fool
March 27, 2008
Brian Lawler |
A Little Bit of Cash for ArQule Development-stage drugmaker ArQule announces that it has received a milestone payment for discovery-stage drug work that it performed for partner Wyeth. |
| <Older 4691-4700 Newer> Return to current articles. |
